LPCN (lipocine.com) Market Value to Book Value Ratio

Official company branding of Lipocine Inc (LPCN)

Lipocine Inc. (LPCN) develops metabolic correction therapies while facing uncertainty due to patent disputes and potential regulatory rejections. The business relies on stable demand, with the current metric standing at 0.55. Long-term growth depends on test results and product commercialization. The share price fluctuations shown below are supplemented by data on production in Utah via third-party contractors.

LPCN Lipocine Corporation: Market Value to Book Value in the range 07/04/2022 - 10/28/2026

Financial and market metric breakdowns for Lipocine Inc (LPCN)

- price and consensus price forecast:
Price Chart Lipocine Inc.|LPCN - Broker Consensus Forecast
- market capitalization data:
Market Value Lipocine Corp|LPCN - Full Business Value
- book capitalization data:
Book Value per Share Lipocine|LPCN - Accounting Value of Company|Market Capitalization to Book Value Ratio lipocine.com|LPCN - Company Total Assets
- debt and liquidity data:
Debt to Equity Lipocine Inc.|LPCN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lipocine Corp|LPCN - Company Total Debt|Debts to Book Capitalization Lipocine Corp|LPCN - Company Long-Term Debts|Company Current Liabilities Lipocine
Initial company analysis:Lipocine Inc. - LPCN
Original product of Lipocine Corp

This ratio determines the market revaluation of the company's net assets. By analyzing the relationship between market capitalization and book value, an investor identifies the premium for future growth. The metric is calculated by dividing the total equity value by the difference between assets and liabilities. For Lipocine Inc. (LPCN), a high variance reflects market expectations regarding its unique drug delivery platform. The current R&D stage makes this indicator a key measure of intellectual capital value.

Main competitors

Market Value to Book Value Ratio Ascendis Pharma A/S|MDGL (madrigalpharma.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Corcept Therapeutics Incorporated CORT|Market Capitalization to Net Assets Rhythm Pharma|Akero Therapeutics Inc (AKRO) - Market Capitalization to Book Value Ratio|Market Value to Book Value Metsera Therapeutics (MTSR)|Market Capitalization to Book Value Ratio MLTX (MoonLake Immunotherapeutics)|crinetics.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio NewAmsterdam Pharma Company N.V. (NAMS)|SLNO: Market Value to Book Value|FOLD (Amicus Pharma) - Market Value to Book Value Ratio|89bio Pharma (ETNB) - Market Cap to Net Assets Ratio|AGIO (Agios Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio structuretx.com (GPCR)|MiMedx (MDXG) - Market Cap to Net Assets Ratio|Market Value to Book Value RZLT (Rezolute Inc)|Lexicon Pharma - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio MBX Corp MBX|ALT (Altimmune, Inc.) - Market Capitalization to Book Value Ratio|aardvarktherapeutics.com (AARD) - Market-to-Book Ratio|SGMT - Market Cap to Net Assets Ratio|BioAge Labs (BIOA) - Market Cap to Book Value Multiple|BMEA (Biomea) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Quince|Market Capitalization to Book Value Ratio Fractyl Health, Inc. (GUTS)|Market Value to Book Value Ratio VTVT (vtvtherapeutics.com)|ATPC: Market Value to Book Value Ratio|Pluristem Therapeutics - Market-to-Book Ratio|SYBX - Market Value to Book Value Ratio|MTNB - Market Value to Book Value Ratio|Spruce Biosciences - Market Capitalization to Book Value Ratio|GLTO (galecto.com) - Market Capitalization to Book Value|CTCX: Market Value to Book Value Ratio|Market Capitalization to Book Value LUMO|Market Value to Book Value Ratio ONVO (Organovo Holdings Inc)|Market Cap to Net Assets Ratio RDUS (Radius Pharmaceuticals)